GILD Share Price

Open 64.37 Change Price %
High 64.75 1 Day -0.06 -0.09
Low 64.31 1 Week 0.14 0.22
Close 64.50 1 Month -4.05 -5.91
Volume 4021883 1 Year -21.32 -24.84
52 Week High 88.85
52 Week Low 63.88
GILD Important Levels
Resistance 2 64.91
Resistance 1 64.74
Pivot 64.52
Support 1 64.26
Support 2 64.09
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
DCTH 0.02 0.00%
SUSQ 14.20 -0.77%
SIRI 5.29 3.32%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
NIHD 0.74 39.62%
NIHD 0.74 39.62%
WRES 0.09 28.57%
CGEI 0.28 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
AEZS 1.18 22.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
CLSN 0.23 -93.11%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Gilead Sciences, Inc. (NASDAQ: GILD)

GILD Technical Analysis 5
As on 26th May 2017 GILD Share Price closed @ 64.50 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 73.99 & Strong Sell for SHORT-TERM with Stoploss of 66.86 we also expect STOCK to react on Following IMPORTANT LEVELS.
GILD Target for May
1st Target up-side 70.33
2nd Target up-side 71.57
3rd Target up-side 72.82
1st Target down-side 66.77
2nd Target down-side 65.53
3rd Target down-side 64.28
GILD Other Details
Segment EQ
Market Capital 51045679104.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.gilead.com
GILD Address
GILD
333 Lakeside Drive
Foster City, CA 94404
United States
Phone: 650-574-3000
Fax: 650-578-9264
GILD Latest News
Interactive Technical Analysis Chart Gilead Sciences, Inc. ( GILD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Gilead Sciences, Inc.
GILD Business Profile
Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead�s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company�s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.